[go: up one dir, main page]

Haddadi et al., 2022 - Google Patents

Signs, symptoms and complications of non-Hodgkin's lymphoma according to grade and stage in south Iran

Haddadi et al., 2022

View PDF
Document ID
10515334303071743683
Author
Haddadi S
Dehghani M
Vojdani R
Publication year
Publication venue
International Journal of Collaborative Research on Internal Medicine & Public Health

External Links

Snippet

Background: Non-Hodgkin's lymphoma (NHL) is a heterogeneous type of neoplasm of the lymphatic system. In order to have a more accurate and early diagnosis we need to be familiar with signs, symptoms and complications of lymphoma in early stages besides …
Continue reading at perpus-utama.poltekkes-malang.ac.id (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Micro-organisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Lee et al. The gut microbiome: what the oncologist ought to know
Martín et al. Faecalibacterium: a bacterial genus with promising human health applications
Qu et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer
Huang et al. Effects of microbiota on anticancer drugs: Current knowledge and potential applications
Longhi et al. Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer immunotherapy
JP7366744B2 (en) Microbiota composition as a marker of reactivity to anti-PD1/PD-L1/PD-L2 antibodies and microbial modulators to improve the efficacy of anti-PD1/PD-L1/PD-L2 antibody-based therapeutic agents. Use of
Xie et al. Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
JP2023029829A (en) Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
Davar et al. Facts and hopes for gut microbiota interventions in cancer immunotherapy
JP2021514968A (en) Microbial immunotherapy
Xie et al. The role of the gut microbiota in tumor, immunity, and immunotherapy
JP2025041753A (en) Treatment of inflammatory bowel disease with 2'-fucosyllactose compounds
Masetti et al. The gut microbiome in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
Shi et al. Emerging roles of the gut microbiota in cancer immunotherapy
CN116709924A (en) Designer bacterial compositions for the treatment of graft-versus-host disease
Yan et al. Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Liu et al. Influence of the gut microbiota on immune cell interactions and cancer treatment
Pham et al. Cancer and immunotherapy: a role for microbiota composition
Wang et al. The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer
Wang et al. Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors
Jamal et al. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
Kumar et al. The cure from within? a review of the microbiome and diet in melanoma
Yu et al. Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+ CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib
Yang et al. Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
Machida et al. Immunotherapy and microbiota for targeting of liver tumor-initiating stem-like cells